{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:58:37Z","timestamp":1792519117561,"version":"4.5.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) have transformed the management of chronic inflammatory diseases. Yet their therapeutic impact extends beyond cytokine suppression, influencing systemic metabolic pathways that are increasingly recognised as central to immune regulation. This narrative review examines the immunometabolic effects of major biologic and targeted synthetic DMARD classes used in dermatologic and rheumatologic diseases. We synthesise evidence on how these agents modulate insulin sensitivity, lipid metabolism, adipokine profiles, mitochondrial function, and adipose-tissue inflammation thereby shaping cardiovascular and metabolic risk. TNF inhibitors show heterogeneous metabolic effects, whereas IL-6 blockade and JAK inhibition consistently improve glycemic parameters despite inducing characteristic lipid changes. IL-17 and IL-23 inhibitors may attenuate adipose inflammation, while TYK2 inhibitors appear metabolically neutral. Through integration of mechanistic insights and clinical data, this review highlights the need to incorporate metabolic phenotyping into therapeutic decision-making. Understanding the distinct metabolic fingerprints of DMARDs may enable more precise patient stratification and support emerging combinatorial strategies with metabolic agents such as GLP-1 receptor agonists and SGLT2 inhibitors. These perspectives underscore the translational importance of viewing DMARD therapies not only as immunomodulators but also as systemic metabolic regulators.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1668159","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T05:31:38Z","timestamp":1770874298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Beyond inflammation: metabolic implications of biological and TsDMARD therapies in dermatologic and rheumatologic diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Salvatore","family":"Corrao","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]},{"name":"Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties [PROMISE], University of Palermo","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Scibetta","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]},{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR)","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Pardo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazio","family":"Cangemi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mirarchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Corrao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Azienda Ospedaliera Universitaria \u201cPoliclinico G. Martino, University of Messina","place":["Messina, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Amodeo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Calvo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Internal Medicine Unit with rheumatology, dermatology, diabetology and tertiary diabetic foot healthcare, National Relevance and High Specialization Hospital Trust ARNAS Civico","place":["Palermo, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI57132","article-title":"Inflammatory links between obesity and metabolic disease","volume":"121","author":"Lumeng","year":"2011","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.04.005","article-title":"Metabolic pathways in immune cell activation and quiescence","volume":"38","author":"Pearce","year":"2013","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.70","article-title":"A guide to immunometabolism for immunologists","volume":"16","author":"O\u2019Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/ar1717","article-title":"Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis","volume":"7","author":"Dessein","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/jcm14041312","article-title":"Therapeutic advancements in psoriasis and psoriatic arthritis","volume":"14","author":"Yi","year":"2025","journal-title":"J Clin Med"},{"key":"B8","article-title":"Anti-TNF-\u03b1 therapy improves insulin resistance in patients with rheumatoid arthritis","volume":"24","author":"Gonzalez-Gay","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15482","article-title":"Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation","volume":"33","author":"Dressler","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr Opin Chem Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/art.24109","article-title":"Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass","volume":"59","author":"Giles","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151159","article-title":"T cell metabolism drives immunity","volume":"212","author":"Buck","year":"2015","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1084\/jem.20151570","article-title":"Immunometabolism governs dendritic cell and macrophage function","volume":"213","author":"O\u2019Neill","year":"2016","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110278","article-title":"HIF1\u03b1-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of Th17 and Treg cells","volume":"208","author":"Shi","year":"2011","journal-title":"J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.06.004","article-title":"Itaconate links inhibition of succinate dehydrogenase with macrophage metabolic remodeling and regulation of inflammation","volume":"24","author":"Lampropoulou","year":"2016","journal-title":"Cell Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802502","article-title":"Inflammatory pathways and insulin action","author":"Hotamisligil","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.12.3391","article-title":"Interleukin-6 induces cellular insulin resistance in hepatocytes","volume":"51","author":"Senn","year":"2002","journal-title":"Diabetes"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI10934","article-title":"Insulin\/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways","volume":"107","author":"Rui","year":"2001","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209459200","article-title":"Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex","volume":"277","author":"Gao","year":"2002","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/me.2008-0264","article-title":"STAT3 targets the regulatory regions of gluconeogenic genes in vivo","volume":"23","author":"Ramadoss","year":"2009","journal-title":"Mol Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545502","article-title":"The \u201cBig Bang\u201d in obese fat: Events initiating obesity-induced adipose tissue inflammation","volume":"45","author":"Wensveen","year":"2015","journal-title":"Eur J Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"R121","DOI":"10.1002\/hep.24001","article-title":"Successful tumor necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis","volume":"13","author":"Biniecka","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.714897","article-title":"Mitochondrial reactive oxygen species are essential for the development of psoriatic inflammation","volume":"12","author":"Mizuguchi","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.21","article-title":"Mitochondrial DNA in innate immune responses and inflammatory pathology","volume":"17","author":"West","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jaci.2021.07.024","article-title":"Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents","volume":"149","author":"Tsoi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.69","article-title":"Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis","volume":"12","author":"Fearon","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.06.039","article-title":"Anti-TNF therapy is associated with improved insulin sensitivity in patients with rheumatoid arthritis","volume":"25","author":"Oguz","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2016.96","article-title":"Effects of anti-TNF-alpha treatment on insulin resistance in patients with rheumatoid arthritis","volume":"57","author":"Seriolo","year":"2008","journal-title":"Pharmacol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"R145","DOI":"10.1038\/nature05698","article-title":"Impact of TNF inhibition on insulin resistance and adipokines in patients with active rheumatoid arthritis: a prospective study","volume":"9","author":"Tam","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001269","article-title":"IL-17 regulates adipogenesis, glucose homeostasis, and obesity","volume":"185","author":"Zuniga","year":"2010","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2016.06.049","article-title":"IL-17A synergistically enhances TNF\u03b1-induced IL-6 and CCL20 production in 3T3-L1 adipocytes","volume":"477","author":"Shinjo","year":"2016","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s42255-021-00371-1","article-title":"Inhibition of the IL-17A axis in adipocytes suppresses diet-induced obesity and metabolic disorders in mice","volume":"3","author":"Teijeiro","year":"2021","journal-title":"Nat Metab"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0094-2","article-title":"\u03b3\u03b4 T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis","volume":"19","author":"Kohlgruber","year":"2018","journal-title":"Nat Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3109\/14397595.2014.934186","article-title":"Effect of secukinumab on aortic vascular inflammation in psoriasis: A randomized placebo-controlled study","volume":"3","author":"Mehta","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jimmunol.2010.09.016","article-title":"Changes in serum adipokine levels in psoriatic patients after anti-IL-23 treatment","volume":"101","author":"Ikumi","year":"2021","journal-title":"J Dermatol Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301977200","article-title":"Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects","volume":"278","author":"Rotter","year":"2003","journal-title":"J Biol Chem"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000888","article-title":"Tocilizumab improves insulin resistance in patients with rheumatoid arthritis","volume":"30","author":"Ogata","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor blockade with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"B44","article-title":"Human CD4+ T cells from adult and neonatal blood are permissive to IL-7 and IL-15 to drive homeostatic proliferation","volume":"9","author":"Yu","year":"2017","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05","article-title":"Explaining how \u201chigh-grade\u201d systemic inflammation accelerates vascular risk in rheumatoid arthritis","volume":"108","author":"Sattar","year":"2003","journal-title":"Circulation"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2002","article-title":"Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters","volume":"15","author":"Feuerer","year":"2009","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e140644","DOI":"10.1172\/jci.insight.140644","article-title":"Tregs facilitate obesity and insulin resistance via a Blimp-1\/IL-10 axis","volume":"6","author":"Beppu","year":"2021","journal-title":"JCI Insight"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e888","DOI":"10.1097\/MD.0000000000000888","article-title":"Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study","volume":"94","author":"Ursini","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/art.40925","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122374","article-title":"Total cholesterol and LDL levels decrease before rheumatoid arthritis","volume":"69","author":"Myasoedova","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"B52","unstructured":"FDA Drug Safety Communication: Safety trial finds increased risk of serious heart-related events, cancer, blood clots, and death with JAK inhibitors"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2249237","article-title":"JAK inhibitors and black box warnings: what is the future for JAK inhibitors","volume":"19","author":"Tokareva","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e26458","DOI":"10.1038\/nrd.2021.15","article-title":"Functional roles of the JAK\/STAT pathway in metabolism","volume":"2","author":"Gunter","year":"2013","journal-title":"JAKSTAT"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22042110","article-title":"Insulin resistance in rheumatoid arthritis: the impact of disease activity, TNF-\u03b1 blockade and corticosteroids","volume":"29","author":"Toms","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/ni1576","article-title":"TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes","volume":"9","author":"Yarilina","year":"2008","journal-title":"Nat Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1178991","article-title":"Tofacitinib suppresses mitochondrial ROS production and reduces synovial inflammation in rheumatoid arthritis","volume":"31","author":"Nishioka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective TYK2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1186\/s12916-022-02646-9","article-title":"The role of TYK2 inhibition in psoriasis: Clinical perspectives and mechanistic insights","volume":"10","author":"Armstrong","year":"2021","journal-title":"J Clin Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03426-1","article-title":"Crucial safety issues on Janus kinase inhibitors in rheumatoid arthritis might be associated with the lack of LDL-cholesterol management: a reasoned literature analysis","volume":"18","author":"Corrao","year":"2023","journal-title":"Intern Emerg Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Body mass index and weight gain in psoriatic arthritis and psoriasis patients treated with biologics and tsDMARDs: A real-world cohort","volume":"10","author":"Bessette","year":"2023","journal-title":"Rheumatol Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B64","doi-asserted-by":"publisher","first-page":"760","DOI":"10.3390\/cells13090760","article-title":"JAK\/STAT inhibition normalizes lipid composition in 3D human epidermal equivalents challenged with Th2 cytokines","volume":"13","author":"Flori","year":"2024","journal-title":"Cells"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13 neutralisation by tralokinumab, an anti-IL-13 antibody","volume":"429","author":"Popovic","year":"2017","journal-title":"J Mol Biol"},{"key":"B66","first-page":"2110","article-title":"Current insights into immunology and novel therapeutics of atopic dermatitis","volume":"22","author":"Kumari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B67","first-page":"35","article-title":"The immunologic and metabolic profile of JAK inhibitors in atopic dermatitis: Understanding lipid changes and safety","volume":"12","author":"Gooderham","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1385720","article-title":"Treatment of atopic dermatitis with upadacitinib: ADCARE single center experience","volume":"11","author":"Fomina","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.1892","article-title":"Obesity is a risk factor for metabolic syndrome and cardiovascular disease in rheumatoid arthritis","volume":"7","author":"Seriolo","year":"2008","journal-title":"Autoimmun Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.jdermsci.2021.01.004","article-title":"Changes in lipids and inflammation in patients with rheumatoid arthritis initiating tocilizumab: results from the CORRONA registry","volume":"17","author":"Navarro-Mill\u00e1n","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.30169","article-title":"The risk of cardiovascular events in rheumatoid arthritis patients treated with tofacitinib: results from the ORAL Surveillance study","volume":"81","author":"Charles-Schoeman","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/art.29686","article-title":"TYK2 inhibitors for the treatment of immune-mediated inflammatory diseases: A selective approach","volume":"20","author":"Mehta","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam8821","article-title":"Infliximab therapy increases body fat mass in rheumatoid arthritis patients with low BMI","volume":"49","author":"Engvall","year":"2010","journal-title":"Rheumatol (Oxford)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000103681.96299.85","article-title":"Adipokine modulation following treatment with IL-23 inhibitors in psoriasis: A biomarker perspective","volume":"49","author":"Ikumi","year":"2022","journal-title":"J Dermatol"},{"key":"B75","first-page":"103188","article-title":"Body weight and composition changes in rheumatoid arthritis patients under targeted therapies: a systematic review and meta-analysis","volume":"21","author":"Hamar","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B76","article-title":"Efficacy and safety of treatments for psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"74","author":"Kristensen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012657","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis na\u00efve to methotrexate: a systematic review and network meta-analysis","volume":"5","author":"Singh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"B78","first-page":"644","article-title":"Treatment of psoriatic patients with biologics in the context of obesity","volume":"9","author":"Gisondi","year":"2018","journal-title":"Front Pharmacol"},{"key":"B79","article-title":"Impact of body weight on the efficacy of biologics in psoriasis: An evidence-based review","volume":"111","author":"Puig","year":"2020","journal-title":"Actas Dermosifiliogr"},{"key":"B80","article-title":"Tocilizumab improves insulin resistance in patients with rheumatoid arthritis","volume":"25","author":"Ikari","year":"2015","journal-title":"Mod Rheumatol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.4161\/jkst.26458","article-title":"Residual inflammation and cardiovascular risk in psoriasis patients on biologic therapy","volume":"11","author":"Bozic","year":"2022","journal-title":"J Clin Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3109\/14397595.2010.508020","article-title":"The role of leptin in the pathophysiology of immune-mediated diseases: Focus on rheumatoid arthritis and systemic lupus erythematosus","volume":"22","author":"Toussirot","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1566","article-title":"Biomarkers of cardiovascular risk in RA: From inflammation to new biosignatures","volume":"18","author":"Peters","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703813","article-title":"Single-cell profiling of psoriasis skin reveals a primary keratinocyte-driven transcriptional inflammatory circuit","volume":"147","author":"Chang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102058","article-title":"Metabolomics in rheumatoid arthritis: Desperately seeking biomarkers","volume":"15","author":"Guma","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jmb.2016.11.034","article-title":"The role of lipidomics in the assessment of cardiovascular risk in psoriasis: a precision medicine approach","volume":"21","author":"Yan","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003613","article-title":"Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets","volume":"186","author":"Michalek","year":"2011","journal-title":"J Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.02.002","article-title":"Mitochondria in the regulation of innate and adaptive immunity","volume":"42","author":"Weinberg","year":"2015","journal-title":"Immunity"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00603-1","article-title":"Immune-mediated inflammatory disease therapeutics: past, present and future","volume":"21","author":"McInnes","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103188","article-title":"The immunology of rheumatoid arthritis","volume":"16","author":"Weyand","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4275","article-title":"Targeting inflammation in the treatment of type 2 diabetes: time to start","volume":"13","author":"Donath","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B95","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1186\/s12916-022-02617-5","article-title":"Psoriasis and cardiovascular disease risk in European and East Asian populations: evidence from meta-analysis and Mendelian randomization analysis","volume":"20","author":"Zhang","year":"2022","journal-title":"BMC Med"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2014.05.007","article-title":"Inflammatory signaling in human adipose tissue: Interactions with hypoxia and mechanistic insights for immunometabolic regulation","volume":"312","author":"Ratter","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"B98","first-page":"e3501","article-title":"Metabolic effects of GLP-1 receptor agonists in patients with chronic inflammatory diseases: A new horizon","volume":"38","author":"Campana","year":"2022","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1668159\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T05:31:41Z","timestamp":1770874301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1668159\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2026.1668159"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1668159","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1668159"}}